Register
Login:
Share:
Email Facebook Twitter




Add Int.biotech. to quick picks

Int.biotech. Share Price (IBT)



Share Price Information for Int.biotech. (IBT)


Share Price: 540.00Bid: 535.50Ask: 540.00Change: 10.00 (+1.89%)Riser - Int.biotech.
Spread: 4.50Spread as %: 0.84%Open: 538.50High: 540.00Low: 538.50Yesterday’s Close: 530.00
InfoGet Live Streaming Prices for IBT - Click here to start your 30 day FREE trial today.


International Biotechnology Trust Plc Ord 25P

Int.biotech. is listed in the FTSE All-Share, FTSE Small Cap
Int.biotech. is part of the Equity Investment Instruments sector






Share Price SpacerPrice
540.00

Share Price SpacerBid
535.50

Share Price SpacerAsk
540.00

Share Price SpacerChange
1.89%10.00

Share Price SpacerVolume
17,741

Share Price SpacerOpen
538.50

Share Price SpacerHigh
540.00

Share Price SpacerLow
538.50

Share Price SpacerClose
530.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 41.39m £223.52m 750

52 Week High 598.00 52 Week High Date 20-MAR-2015
52 Week Low 230.00 52 Week Low Date 14-APR-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
13 4,591 13,150 0.000 0.00 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

31-Mar-15
08:02:54
535.80
1,938
Sell* 
535.50
540.00
10.38k
Trade Type:
Ordinary

31-Mar-15
08:50:29
538.875
278
Buy* 
535.50
540.00
1,498
Trade Type:
Ordinary
Deletion

31-Mar-15
08:46:04
538.875
742
Buy* 
535.50
540.00
3,998
Trade Type:
Ordinary
Deletion


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Int.biotech. trades >>

Directors Deals for Int.biotech. (IBT)
Trade DateActionNotifierPriceCurrencyAmountHolding
28-Feb-14Buy
Trade Notifier Information for International Biotech Trust
Jim Horsburgh held the position of Non-Executive Director at International Biotech Trust at the time of this trade.
 Jim Horsburgh
330.94GBX5,0000
26-Jun-13Buy
Trade Notifier Information for International Biotech Trust
Jim Horsburgh held the position of Non-Executive Director at International Biotech Trust at the time of this trade.
 Jim Horsburgh
250.74GBX5,0005000
09-Feb-12Buy
Trade Notifier Information for International Biotech Trust
Veronique Bouchet held the position of Non-Executive Director at International Biotech Trust at the time of this trade.
 Veronique Bouchet
187.5GBX5,0005000
View more Int.biotech. directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Thu 21:28
Laughton
RE: Is
522.00
No Opinion

Could be a good topping up point. I still feel that biotech has a lot of life left in it - and these people definitely know what they're doing.
Wed 19:36
cmc_686
Is
535.50
No Opinion

it heading to hell now?
Wed 18:16
Laughton
Price Drop
535.50
No Opinion

Ouch!
Wed 14:11
cmc_686
Wholy
554.50
No Opinion

****! Rubbish!
5 Mar '15
Laughton
Pharmacyclics deal (3% of NAV)
522.00
No Opinion

(Reuters) - AbbVie Inc (ABBV.N) is to buy Pharmacyclics Inc (PCYC.O) for about $21 billion, giving it access to what is expected to be one of the world's top-selling cancer drugs and expanding its reach in the profitable oncology field. The deal -- the latest example of a big drugmaker swooping on a biotech firm to refill its medicine pipeline -- confounds expectations that Pharmacyclics would sell out to Johnson & Johnson (JNJ.N). AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday. Back in 2008 and 2009, the shares dipped below $1. The acquisition lessens Chicago-based AbbVie's dependence on its blockbuster rheumatoid arthritis drug Humira that accounts for most of its revenue but is expected to start to see sales decline from 2017 or 2018. AbbVie failed last October to buy Dublin-based Shire Plc (SHP.L) for $55 billion after the United States took steps to deter such tax-lowering deals. Deutsche Bank analyst Robyn Karnauskas said the deal was positive for AbbVie as Pharmacyclics' blood cancer treatment Imbruvica would diversify the business beyond Humira. "Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical efficacy across a broad range of hematologic malignancies," AbbVie Chief Executive Richard Gonzalez said in a statement. Pharmacyclics expects U.S. sales of Imbruvica to hit $1 billion this year and by 2020 worldwide sales are forecast to reach $5.8 billion, according to consensus analyst estimates compiled by Thomson Reuters Cortellis. AbbVie, which was spun out of Abbott Laboratories in 2013, said the deal would be "highly accretive" to its revenue and earnings by 2017. Sunnyvale, California-based Pharmacyclics co-markets Imbruvica with Johnson & Johnson. Besides Imbruvica, it has three product candidates in development. In a statement, J&J said: “We’re looking forward to continuing our collaboration with the team at AbbVie to further develop and commercialize this important therapy for patients and their health care teams.” Media reports had said J&J was close to buying Pharmacyclics. Novartis AG (NOVN.VX) was also interested in the company, a report said. The acquisition is the latest in a spate of big pharma deals this year as many companies are strengthening their portfolios as old drugs go generic. Last month, Pfizer Inc (PFE.N) agreed to buy Hospira Inc (HSP.N) for about $15 billion, and Canada's Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) agreed to buy Salix Pharmaceuticals Ltd (SLXP.O) for about $10 billion. The deal, expected to close in the middle of the year, comprises about 58 percent cash and 42 percent AbbVie common stock. Pharmacyclics shareholders can opt for cash, AbbVie stock or a combination, AbbVie said.
27 Feb '15
Lemonhead
RE: up 300% no1 talks here
497.25
No Opinion

I bought these in October 2014 @ 3.70 and I intend to hold long term

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Int.biotech. (IBT) >>
Please Login or Register to post messages






Sign up for Live Prices


CD02WL.001.081313


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.